The World's Most Successful Failure

By Carmichael, Mary | Newsweek, February 22, 2010 | Go to article overview

The World's Most Successful Failure


Carmichael, Mary, Newsweek


Byline: Mary Carmichael

Iceland's deCODE has discovered more genes than any other company on earth. If only it could turn a profit.

During the late 1990s, it was an article of faith that the decade ahead would be the Age of Biotech, an era when science would unravel the mysteries of DNA to determine the causes--and potentially the cures s--of the world's most common ailments: heart disease, cancer, mental illness. But even in an industry accustomed to hype, one company stood out: a small Icelandic startup called deCODE. In 1999 The New Yorker ran a glowing 10-page profile with a portrait of Kari Stefansson, the company's charismatic founder, climbing the DNA double helix like a ladder. DeCODE, it said, had "a scientific instrument of unparalleled power." Over the next 10 years, deCODE discovered so many genes linked to diseases that its only competitors were top U.S. labs lavishly funded by the National Institutes of Health. What it didn't find, however, was a business model that made sense--a common problem in the speculative, science-driven world of biotech. That, plus the global financial crisis, caused it to burn through $676 million, and last November it went bankrupt.

DeCODE's story is dramatic, but these days it's a common narrative arc. The recession has been tough on every company, but it's been particularly virulent toward startups, which usually lack profits and capital, giving them little margin for error when revenue falls and credit tightens. Typically, when a startup goes bust, it's gone forever--but deCODE hopes to be the exception. In the last two months, it's been recapitalized by outside investors, and now the company is emerging from bankruptcy with new leadership and a new strategy. There's still much that can go wrong: its new model isn't proved; there are early signs its new CEO's strategy may conflict with its visionary founder, who remains on the scene; and the company's culture, which has always shown more reverence for science than for profits, will need an overhaul. But in an environment where few companies of its size get a shot at resurrection, deCODE's second act is shaping up to be one of the biotech industry's most interesting experiments.

To say that deCODE launched big is like saying its home country of Iceland gets a bit chilly. As a group, Icelanders are closely related, which means when they get sick, there's a limited subset of genes that can be blamed. They also keep extensive genealogical records. Stefansson's insight was to put their genes and genealogy together and search the results for the roots of disease. Initially, he hoped to analyze the medical histories of all 277,000 of his countrymen through an exclusive government deal. That plan alarmed some bioethicists, who accused the company of profiteering and putting its subjects' privacy at risk. (Stefansson's dismissal of their concerns in The New Yorker as "a horrendous crock of s--t" probably didn't help his case.) Ultimately, the plan was ruled unconstitutional. Still, deCODE was able to gather genetic information from 140,000 Icelandic volunteers, and its database made it one of the world's top players in biotech.

What deCODE did with its data was the first step toward its financial downfall, though no one suspected it at the time. The company's original plan had been to focus on making diagnostic tests, but investors were lukewarm tothat idea. Diagnostics, which use genetic material (like a cheek swab or blood sample) to test for the presence of certain genes, are tricky to bring to market, and at the time, the technology for making them was somewhat primitive. The way venture capitalists saw it, drugs were a more proven route to profits. If deCODE could discover even one gene with a large effect on a common condition like heart disease, the thinking went, it would provide an obvious pharmaceutical target and a way to rake in cash. So in 1998, deCODE signed a $200 million drug-discovery deal with F.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

The World's Most Successful Failure
Settings

Settings

Typeface
Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.